Issue Archive

Understanding the pathogenesis of drug-induced immune thrombocytopenia is the key to better patient management. In this issue of Blood, Bougie and colleagues provide further useful insights into the mechanism of thrombocytopenia caused by arginine-glycine-aspartic acid (RGD) mimetic drugs.¹ 

In this issue of Blood, Lokhorst et al report the results of a donor versus no-donor comparison trial, which unambiguously establishes that reduced intensity conditioning allogeneic stem cell transplantation (RIC allo-SCT) should not be offered as part of frontline therapy in multiple myeloma (MM).¹ 

In this issue of Blood, Granados et al explore the relationship between the cellular transcriptome and immunopeptidome,^1,2  the repertoire of peptides presented by MHC class I molecules for immunosurveillance.

In this issue of Blood, Chakraborty and colleagues provide conclusive proof that primary chronic myeloid leukemia (CML) cells from patients in chronic phase demonstrate chromosomal instability after DNA damage, suggesting that BCR/ABL, among its myriad described functions, dysregulates nonhomologous end joining (NHEJ) starting the progression of cells toward CML blast crisis.¹ 

In this issue of Blood, Busch and colleagues examine the risk of hepatitis C virus (HCV) transmission by plasma collected before HCV is detectable by licensed clinical assays.¹ 

In this issue of Blood, studies by Rangarajan et al comprehensively analyzing the clonotypic T-cell response provide evidence that the effector T cells that mediate chronic GVHD may have a unique specificity that includes recognition of self.¹